RXST Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -14.77% compared to RxSight's net margin of --. RxSight's return on equity of -11.86% beat Perspective Therapeutics's return on equity of --.

RxSight has a consensus price target of $24.36, signalling upside risk potential of 68.84%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 641.9%. Given that Perspective Therapeutics has higher upside potential than RxSight, analysts believe Perspective Therapeutics is more attractive than RxSight.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $40.2M, which are larger than Perspective Therapeutics quarterly revenues of --. RxSight's net income of -$5.9M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, RxSight's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 4.01x versus 12.56x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

PROCEPT BioRobotics has a net margin of -14.77% compared to RxSight's net margin of -27.63%. RxSight's return on equity of -11.86% beat PROCEPT BioRobotics's return on equity of -31.74%.

RxSight has a consensus price target of $24.36, signalling upside risk potential of 68.84%. On the other hand PROCEPT BioRobotics has an analysts' consensus of $90.88 which suggests that it could grow by 71.37%. Given that PROCEPT BioRobotics has higher upside potential than RxSight, analysts believe PROCEPT BioRobotics is more attractive than RxSight.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PROCEPT BioRobotics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PROCEPT BioRobotics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. PROCEPT BioRobotics pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $40.2M, which are smaller than PROCEPT BioRobotics quarterly revenues of $68.2M. RxSight's net income of -$5.9M is higher than PROCEPT BioRobotics's net income of -$18.9M. Notably, RxSight's price-to-earnings ratio is -- while PROCEPT BioRobotics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 4.01x versus 12.31x for PROCEPT BioRobotics. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -14.77% compared to RxSight's net margin of -1226.82%. RxSight's return on equity of -11.86% beat VolitionRX's return on equity of --.

RxSight has a consensus price target of $24.36, signalling upside risk potential of 68.84%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 496.74%. Given that VolitionRX has higher upside potential than RxSight, analysts believe VolitionRX is more attractive than RxSight.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $40.2M, which are larger than VolitionRX quarterly revenues of $474.5K. RxSight's net income of -$5.9M is lower than VolitionRX's net income of -$5.8M. Notably, RxSight's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 4.01x versus 34.38x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -14.77% compared to RxSight's net margin of -10.04%. RxSight's return on equity of -11.86% beat Xtant Medical Holdings's return on equity of -35.34%.

RxSight has a consensus price target of $24.36, signalling upside risk potential of 68.84%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 289.76%. Given that Xtant Medical Holdings has higher upside potential than RxSight, analysts believe Xtant Medical Holdings is more attractive than RxSight.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $40.2M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. RxSight's net income of -$5.9M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, RxSight's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 4.01x versus 0.51x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.